Emerging drugs for treating the acute respiratory distress syndrome

References

• Petty TL, Ashbaugh DG. The adult respiratory distress syndrome. Clinical features, factors influencing prognosis and principles of management. Chest. 1971;60(3):233–239.
   PubMed Web of Science ®Google Scholar
• Murray JF, Matthay MA, Luce JM, et al. An expanded definition of the adult respiratory distress syndrome. Am Rev Respir Dis. 1988;138(3):720–723.
   PubMed Web of Science ®Google Scholar
• Bernard GR, Artigas A, Brigham KL, et al. The American-European consensus conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med. 1994;149(3):818–824.
   PubMed Web of Science ®Google Scholar
• The ARDS Definition Task Force. Acute respiratory distress syndrome. The berlin definition. JAMA. 2012;307(23):2526–2533.
   PubMed Web of Science ®Google Scholar
• Laffey JG, Pham T, Bellani G. Continued under-recognition of acute respiratory distress syndrome after the Berlin definition: what is the solution? Curr Opin Crit Care. 2017;23(1):10–17.
   PubMed Web of Science ®Google Scholar
• Rubenfeld GD, Caldwell E, Peabody E, et al. Incidence and outcomes of acute lung injury. N Engl J Med. 2005;353(16):1685–1693.
   PubMed Web of Science ®Google Scholar
• Villar J, Blanco J, Añón JM, et al. The ALIEN study: incidence and outcome of acute respiratory distress syndrome in the era of lung protective ventilation. Intensive Care Med. 2011;37(12):1932–1941.
   PubMed Web of Science ®Google Scholar
• Bellani G, Laffey JG, Pham T, et al. Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries. JAMA. 2016;315(8):788–800.
   PubMed Web of Science ®Google Scholar
• Umbrello M, Formenti P, Bolgiaghi L, et al. Current concepts of ARDS: a narrative review. Int J Mol Sci. 2016;18(1):E64.
   PubMed Web of Science ®Google Scholar
• Tejera P, Meyer NJ, Chen F, et al. Distinct and replicable genetic risk factors for acute respiratory distress syndrome of pulmonary or extrapulmonary origin. J Med Genet. 2012;49(11):671–680.
   PubMed Web of Science ®Google Scholar
• Sharp C, Millar AB, Medford AR. Advances in understanding of the pathogenesis of acute respiratory distress syndrome. Respiration. 2015;89(5):420–434.
   PubMed Web of Science ®Google Scholar
• Muir R, Osbourn M, Dubois AV. Innate lymphoid cells are the predominant source of IL-17A during the early pathogenesis of acute respiratory distress syndrome. Am J Respir Crit Care Med. 2016;193(4):407–416.
   PubMed Web of Science ®Google Scholar
• Mac Sweeney R, McAuley DF. Acute respiratory distress syndrome. Lancet. 2016;388(10058):2416–2430.
   PubMed Web of Science ®Google Scholar
• Zochios V, Parhar K, Tunnicliffe W, et al. The right ventricle in ARDS. Chest. 2017;152(1):181–193.
   PubMed Web of Science ®Google Scholar
• Shyamsundar M, McAuley DF, Ingram RJ, et al. Keratinocyte growth factor promotes epithelial survival and resolution in a human model of lung injury. Am J Respir Crit Care Med. 2014;189(12):1520–1529.
   PubMed Web of Science ®Google Scholar
• Cabrera-Benitez NE, Laffey JG, Parotto M, et al. Mechanical ventilation-associated lung fibrosis in acute respiratory distress syndrome: a significant contributor to poor outcome. Anesthesiology. 2014;121(1):189–198.
   PubMed Web of Science ®Google Scholar
• Sigurdsson MI, Sigvaldason K, Gunnarsson TS. Acute respiratory distress syndrome: nationwide changes in incidence, treatment and mortality over 23 years. Acta Anaesthesiol Scand. 2013;57(1):37–45.
   PubMed Web of Science ®Google Scholar
• Máca J, Jor O, Holub M, et al. Past and present ARDS mortality rates: a systematic review. Respir Care. 2017;62(1):113–122.
   PubMed Web of Science ®Google Scholar
• Prescott HC, Sjoding MW, Langa KM, et al. Late mortality after acute hypoxic respiratory failure. Thorax. 2017;73:618–625.
   Web of Science ®Google Scholar
• Herridge MS, Tansey CM, Matté A, et al. Functional disability 5 years after acute respiratory distress syndrome. N Engl J Med. 2011;364(14):293–304.
   PubMed Web of Science ®Google Scholar
• Kapfhammer HP, Rothenhäusler HB, Krauseneck T, et al. Posttraumatic stress disorder and health-related quality of life in long-term survivors of acute respiratory distress syndrome. Am J Psychiatry. 2004;161(1):45–52.
   PubMed Web of Science ®Google Scholar
• Gebistorf F, Karam O, Wetterslev J, et al. Inhaled nitric oxide for acute respiratory distress syndrome (ARDS) in children and adults (Review). Cochrane Database Syst Rev. 2016;6:CD002787.
   Google Scholar
• Nagendran M, McAuley DF, Kruger PS, et al. Statin therapy for acute respiratory distress syndrome: an individual patient data meta-analysis of randomised clinical trials. Intensive Care Med. 2017;45(5):663–671.
   Google Scholar
• Khan A, Benthin C, Zeno B, et al. A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome. Crit Care. 2017;21(1):234.
   PubMedGoogle Scholar
• Krenn K, Lucas R, Croizé A, et al. Inhaled AP301 for treatment of pulmonary edema in mechanically ventilated patients with acute respiratory distress syndrome: a phase IIa randomized placebo-controlled trial. Crit Care. 2017;21:194.
   PubMed Web of Science ®Google Scholar
• Willson DF, Truwit JD, Conaway MR, et al. The adult calfactant in acute respiratory distress syndrome trial. Chest. 2015;148(2):356–364.
   PubMed Web of Science ®Google Scholar
• Liu KD, Levitt J, Zhuo H, et al. Randomized clinical trial of activated protein C for the treatment of acute lung injury. Am J Respir Crit Care Med. 2008;178(6):618–623.
   PubMed Web of Science ®Google Scholar
• Fan E, Del Sorbo L, Goligher EC, et al. An official American thoracic society/European society of intensive care medicine/Society of critical care medicine clinical practice guideline: mechanical ventilation in adult patients with acute respiratory distress syndrome. Am J Respir Crit Care Med. 2017;195(9):1253–1263.
   PubMed Web of Science ®Google Scholar
• Blackwood B, Ringrow S, Clarke M, et al. Core Outcomes in Ventilation Trials (COVenT): protocol for a core outcome set using a Delphi survey with a nested randomised trial and observational cohort study. Trials. 2015;16:368.
   PubMed Web of Science ®Google Scholar
• Silversides JA, Major E, Ferguson AJ, et al. Conservative fluid management or deresuscitation for patients with sepsis or acute respiratory distress syndrome following the resuscitation phase of critical illness: a systematic review and meta-analysis. Intensive Care Med. 2017;43(2):155–170.
   PubMed Web of Science ®Google Scholar
• Famous KR, Delucchi K, Ware LB, et al. Acute respiratory distress syndrome subphenotypes respond differently to randomized fluid management strategy. Am J Respir Crit Care Med. 2017;195(3):331–338.
   PubMed Web of Science ®Google Scholar
• Mikkelsen ME, Christie JD, Lanken PN, et al. The adult respiratory distress syndrome cognitive outcomes study: long-term neuropsychological function in survivors of acute lung injury. Am J Respir Crit Care Med. 2012;185(12):1307–1315.
   PubMed Web of Science ®Google Scholar
• Alhazzani W, Alshahrani M, Jaeschke R, et al. Neuromuscular blocking agents in acute respiratory distress syndrome: a systematic review and meta-analysis of randomized controlled trials. Crit Care. 2013;17(2):R43.
   PubMed Web of Science ®Google Scholar
• Guervilly C, Bisbal M, Forel JM, et al. Effects of neuromuscular blockers on transpulmonary pressures in moderate to severe acute respiratory distress syndrome. Intensive Care Med. 2017;43(3):408–418.
   PubMed Web of Science ®Google Scholar
• Murray MJ, DeBlock HF, Erstad BL, et al. Clinical practice guidelines for sustained neuromuscular blockade in the adult critically ill patient: 2016 update-executive summary. Am J Health Syst Pharm. 2017;74(2):76–78.
   PubMed Web of Science ®Google Scholar
• Agus A, Hulme C, Verghis RM, et al. Simvastatin for patients with Acute Respiratory Distress Syndrome: long term outcomes and cost-effectiveness from a randomised controlled trial. Crit Care. 2017;21(1):108.
   PubMedGoogle Scholar
• Marti J, Hall P, Hamilton P, et al. One-year resource utilisation, costs and quality of life in patients with acute respiratory distress syndrome (ARDS): secondary analysis of a randomised controlled trial. J Intensive Care. 2016;4:56.
   PubMed Web of Science ®Google Scholar
• Ruhl AP, Lord RK, Panek JA, et al. Health care resource use and costs of two-year survivors of acute lung injury. An observational cohort study. Ann Am Thorac Soc. 2015;12(3):392–401.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Guide to the methods of technology appraisal. London: NICE Process and Methods Guides; 2013.
   Google Scholar
• Peek GJ, Elbourne D, Mugford M, et al. Randomised controlled trial and parallel economic evaluation of conventional ventilatory support versus extracorporeal membrane oxygenation for severe adult respiratory failure (CESAR). Health Technol Assess. 2010;14(35):1–46.
   PubMed Web of Science ®Google Scholar
• Proudfoot AG, McAuley DF, Griffiths MJ, et al. Human models of acute lung injury. Dis Model Mech. 2011;4(2):145–153.
   PubMed Web of Science ®Google Scholar
• Shyamsundar M, McKeown ST, O’Kane CM, et al. Simvastatin decreases lipopolysaccharide-induced pulmonary inflammation in healthy volunteers. Am J Respir Crit Care Med. 2009;179(12):1107–1114.
   PubMed Web of Science ®Google Scholar
• Carden DL, Granger DN. Pathophysiology of ischaemia-reperfusion injury. J Pathol. 2000;190:255–266.
   PubMed Web of Science ®Google Scholar
• Yin K, Gribbin E, Emanuel S, et al. Histochemical alterations in one lung ventilation. J Surg Res. 2007;137:16–20.
   PubMed Web of Science ®Google Scholar
• Alam N, Park BJ, Wilton A, et al. Incidence and risk factors for lung injury after lung cancer resection. Ann Thorac Surg. 2007;84:1085–1091.
   PubMed Web of Science ®Google Scholar
• Hamid U, Krasnodembskaya A, Fitzgerald M, et al. Aspirin reduces lipopolysaccharide-induced pulmonary inflammation in human models of ARDS. Thorax. 2017;72(11):971–980.
   PubMed Web of Science ®Google Scholar
• Boyle AJ, McNamee JJ, McAuley DF. Biological therapies in the acute respiratory distress syndrome. Expert Opin Biol Ther. 2014;14(7):969–981.
   PubMed Web of Science ®Google Scholar
• McAuley DF, Cross LM, Hamid U, et al. Keratinocyte growth factor for the treatment of the acute respiratory distress syndrome (KARE): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Respir Med. 2017;5(6):484–491.
   PubMed Web of Science ®Google Scholar
• Perkins GD, McAuley DF, Thickett DR, et al. The beta-agonist lung injury trial (BALTI): a randomized placebo-controlled clinical trial. Am J Respir Crit Care Med. 2006;173:281–287.
   PubMed Web of Science ®Google Scholar
• Perkins GD, Nathani N, McAuley DF, et al. In vitro and in vivo effects of salbutamol on neutrophil function in acute lung injury. Thorax. 2007;62(1):36–42.
   PubMed Web of Science ®Google Scholar
• Matthay MA, Brower RG, Carson S, et al. Randomized, placebo-controlled clinical trial of an aerosolized β₂-agonist for treatment of acute lung injury. Am J Respir Crit Care Med. 2011;184(5):561–568.
   PubMed Web of Science ®Google Scholar
• Gao Smith F, Perkins GD, Gates S, et al. Effect of intravenous β-2 agonist treatment on clinical outcomes in acute respiratory distress syndrome (BALTI-2): a multicentre, randomised controlled trial. Lancet. 2012;279(9812):229–235.
   Google Scholar
• Asmussen S, Ito H, Traber D, et al. Human mesenchymal stem cells reduce the severity of acute lung injury in a sheep model of bacterial pneumonia. Thorax. 2014;69:819–825.
   PubMed Web of Science ®Google Scholar
• McAuley DF, Curley GF, Hamid UI, et al. Clinical grade allogeneic human mesenchymal stem cells restore alveolar fluid clearance in human lungs rejected for transplantation. Am J Physiol Lung Cell Mol Physiol. 2014;306(9):L809–L815.
   PubMed Web of Science ®Google Scholar
• Morrison TJ, Jackson MV, Cunningham EK, et al. Mesenchymal stromal cells modulate macrophages in clinically relevant lung injury models by extracellular vesicle mitochondrial transfer. Am J Respir Crit Care Med. 2017;196:1275–1286.
   PubMed Web of Science ®Google Scholar
• Jackson MV, Morrison TJ, Doherty DF, et al. Mitochondrial transfer via tunneling nanotubes is an important mechanism by which mesenchymal stem cells enhance macrophage phagocytosis in the in vitro and in vivo models of ARDS. Stem Cells. 2016;34(8):2210–2223.
   PubMed Web of Science ®Google Scholar
• Wilson JG, Liu KD, Zhuo H, et al. Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial. Lancet Respir Med. 2015;3(1):24–32.
   PubMed Web of Science ®Google Scholar
• Matthay MA, Calfee CS, Zhuo H, et al. Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial. Lancet Respir Med. 2019;7:154–162.
   PubMed Web of Science ®Google Scholar
• Ware LB, Kaner RJ, Crystal RG, et al. VEGF levels in the alveolar compartment do not distinguish between ARDS and hydrostatic pulmonary oedema. Eur Respir J. 2005;26(1):101–105.
   PubMed Web of Science ®Google Scholar
• van der Poll T, Levi M, Nick JA, et al. Activated protein C inhibits local coagulation after intrapulmonary delivery of endotoxin in humans. Am J Respir Crit Care Med. 2005;171(10):1125–1128.
   PubMed Web of Science ®Google Scholar
• Cornet AD, Groeneveld AB, Hofstra JJ, et al. Recombinant human activated protein C in the treatment of acute respiratory distress syndrome: a randomized clinical trial. PLoS One. 2014;9(3):e90983.
   PubMed Web of Science ®Google Scholar
• Meduri GU, Bridges L, Shih MC, et al. Prolonged glucocorticoid treatment is associated with improved ARDS outcomes: analysis of individual patients’ data from four randomized trials and trial-level meta-analysis of the updated literature. Intensive Care Med. 2016;42(5):829–840.
   PubMed Web of Science ®Google Scholar
• Tongyoo S, Permpikul C, Mongkolpun W, et al. Hydrocortisone treatment in early sepsis-associated acute respiratory distress syndrome: results of a randomized controlled trial. Crit Care. 2016;20(1):329.
   PubMedGoogle Scholar
• Ruan SY, Lin HH, Huang CT, et al. Exploring the heterogeneity of effects of corticosteroids on acute respiratory distress syndrome: a systematic review and meta-analysis. Crit Care. 2014;18(2):R63.
   PubMed Web of Science ®Google Scholar
• Horita N, Hashimoto S, Miyazawa N, et al. Impact of corticosteroids on mortality in patients with acute respiratory distress syndrome: a systematic review and meta-analysis. Intern Med. 2015;54(12):1473–1479.
   PubMed Web of Science ®Google Scholar
• Claesson J, Freundlich M, Gunnarsson I, et al. Scandinavian clinical practice guideline on fluid and drug therapy in adults with acute respiratory distress syndrome. Acta Anaesthesiol Scand. 2016;60(6):697–709.
   PubMed Web of Science ®Google Scholar
• Villar J, Belda J, Añón JM, et al. Evaluating the efficacy of dexamethasone in the treatment of patients with persistent acute respiratory distress syndrome: study protocol for a randomized controlled trial. Trials. 2016;17:342.
   PubMed Web of Science ®Google Scholar
• Festic E, Carr GE, Cartin-Ceba R, et al. Randomized clinical trial of a combination of an inhaled corticosteroid and beta agonist in patients at risk of developing the acute respiratory distress syndrome. Crit Care Med. 2017;45(5):798–805.
   PubMed Web of Science ®Google Scholar
• Matthay MA, McAuley DF, Ware LB. Clinical trials in acute respiratory distress syndrome: challenges and opportunities. Lancet Respir Med. 2017;5(6):524–534.
   PubMed Web of Science ®Google Scholar
• Kiss J, Yegutkin GG, Koskinen K, et al. IFN-beta protects from vascular leakage via up-regulation of CD73. Eur J Immunol. 2007;37(12):3334–3338.
   PubMed Web of Science ®Google Scholar
• Faron Pharmaceuticals Ltd. Top line data from the Phase III INTEREST trial. 2018. [cited 2019 Feb 8]. Available from: https://otp.tools.investis.com/clients/uk/faron/rns/regulatory-story.aspx?cid=2223&newsid=1007071
   Google Scholar
• Zhang Y, Leung DY, Richers BN, et al. Vitamin D inhibits monocyte/macrophage proinflammatory cytokine production by targeting MAPK phosphatase-1. J Immunol. 2012;188(5):2127–2135.
   PubMed Web of Science ®Google Scholar
• Dancer RC, Parekh D, Lax S, et al. Vitamin D deficiency contributes directly to the acute respiratory distress syndrome (ARDS). Thorax. 2015;70(7):617–624.
   PubMed Web of Science ®Google Scholar
• Parekh D, Dancer RC, Lax S, et al. Vitamin D to prevent acute lung injury following oesophagectomy (VINDALOO): study protocol for a randomised placebo controlled trial. Trials. 2013;14:100.
   PubMed Web of Science ®Google Scholar
• Toner P, McAuley DF, Shyamsundar M. Aspirin as a potential treatment in sepsis or acute respiratory distress syndrome. Crit Care. 2015;19:374.
   PubMed Web of Science ®Google Scholar
• Harr JN, Moore EE, Johnson J, et al. Anti-platelet therapy is associated with decreased transfusion-associated risk of lung dysfunction, multiple organ failure, and mortality in trauma patients. Crit Care Med. 2013;41(2):399–404.
   PubMed Web of Science ®Google Scholar
• Kor DJ, Carter RE, Park PK, et al. Effect of aspirin on development of ARDS in at-risk patients presenting to the emergency department: the LIPS-A randomized clinical trial. JAMA. 2016;315(22):2406–2414.
   PubMed Web of Science ®Google Scholar
• Athersys Inc. Press Release: Athersys Announces Positive Results From Its Exploratory Clinical Study of MultiStem® Cell Therapy for Treatment of Acute Respiratory Distress Syndrome (ARDS). 2019. [cited 2019 Feb 8]. Available from: https://athersysinc.gcs-web.com/news-releases/news-release-details/athersys-announces-positive-results-its-exploratory-clinical
   Google Scholar
• Fisher BJ, Kraskauskas D, Martin EJ, et al. Mechanisms of attenuation of abdominal sepsis induced acute lung injury by ascorbic acid. Am J Physiol Lung Cell Mol Physiol. 2012;30(1):L20–L32.
   Google Scholar
• Borrelli E, Roux-Lombard P, Grau GE, et al. Plasma concentrations of cytokines, their soluble receptors, and antioxidant vitamins can predict the development of multiple organ failure in patients at risk. Crit Care Med. 1996;24(3):392–397.
   PubMed Web of Science ®Google Scholar
• Hemilä H, Louhiala P. Vitamin C for preventing and treating pneumonia (Review). Cochrane Database Syst Rev. 2013;1(8):CD005532.
   PubMed Web of Science ®Google Scholar
• Sebag SC, Bastarache JA, Ware LB. Therapeutic modulation of coagulation and fibrinolysis in acute lung injury and the acute respiratory distress syndrome. Curr Pharm Biotechnol. 2011;12(9):1481–1496.
   PubMed Web of Science ®Google Scholar
• Dixon B, Schultz MJ, Smith R, et al. Nebulized heparin is associated with fewer days of mechanical ventilation in critically ill patients: a randomized controlled trial. Crit Care. 2010;14(5):R180.
   PubMed Web of Science ®Google Scholar
• Morris PE, Steingrub JS, Huang BY, et al. A phase I study evaluating the pharmacokinetics, safety and tolerability of an antibody-based tissue factor antagonist in subjects with acute lung injury or acute respiratory distress syndrome. BMC Pulm Med. 2012;12:5.
   PubMed Web of Science ®Google Scholar
• Denham W, Yang J, Wang H, et al. Inhibition of p38 mitogen activate kinase attenuates the severity of pancreatitis-induced adult respiratory distress syndrome. Crit Care Med. 2000;28(7):2567–2572.
   PubMed Web of Science ®Google Scholar
• Christie JD, Vaslef S, Chang PK, et al. A randomized dose-escalation study of the safety and anti-inflammatory activity of the p38 mitogen-activated protein kinase inhibitor dilmapimod in severe trauma subjects at risk for acute respiratory distress syndrome. Crit Care Med. 2015;43(9):1859–1869.
   PubMed Web of Science ®Google Scholar
• Honiden S, Schultz A, Im SA, et al. Early versus late intravenous insulin administration in critically ill patients. Intensive Care Med. 2008;34(5):881–887.
   PubMed Web of Science ®Google Scholar
• Shapiro H, Kagan I, Shalita-Chesner M, et al. Inhaled aerosolized insulin: a “topical” anti-inflammatory treatment for acute lung injury and respiratory distress syndrome? Inflammation. 2010;33(5):315–319.
   PubMed Web of Science ®Google Scholar
• Iwata K, Doi A, Ohji G, et al. Effect of neutrophil elastase inhibitor (sivelestat sodium) in the treatment of acute lung injury (ALI) and acute respiratory distress syndrome (ARDS): a systematic review and meta-analysis. Intern Med. 2010;49(22):2423–2432.
   PubMed Web of Science ®Google Scholar
• Zeiher BG, Artigas A, Vincent JL, et al. Neutrophil elastase inhibition in acute lung injury: results of the STRIVE study. Crit Care Med. 2004;32(8):1695–1702.
   PubMed Web of Science ®Google Scholar
• Tagami T, Tosa R, Omura M, et al. Effect of a selective neutrophil elastase inhibitor on mortality and ventilator-free days in patients with increased extravascular lung water: a post hoc analysis of the PiCCO Pulmonary Edema Study. J Intensive Care. 2014;2(1):67.
   PubMedGoogle Scholar
• Cao YZ, Tu YY, Chen X, et al. Protective effect of Ulinastatin against murine models of sepsis: inhibition of TNF-α and IL-6 and augmentation of IL-10 and IL-13. Exp Toxicol Pathol. 2012;64(6):543–547.
   PubMed Web of Science ®Google Scholar
• Leng YX, Yang SG, Song YH, et al. Ulinastatin for acute lung injury and acute respiratory distress syndrome: A systematic review and meta-analysis. World J Crit Care Med. 2014;3(1):34–41.
   PubMedGoogle Scholar
• Paine R 3rd, Standiford TJ, Dechert RE, et al. A randomized trial of recombinant human granulocyte-macrophage colony stimulating factor for patients with acute lung injury. Crit Care Med. 2012;40(1):90–97.
   PubMed Web of Science ®Google Scholar
• Frevert CW, Matute-Bello G, Skerrett SJ, et al. Effect of CD14 blockade in rabbits with Escherichia coli pneumonia and sepsis. J Immunol. 2000;164(10):5439–5445.
   PubMed Web of Science ®Google Scholar
• Puri N, Dellinger RP. Inhaled nitric oxide and inhaled prostacyclin in acute respiratory distress syndrome: what is the evidence? Crit Care Clin. 2011;27(3):561–587.
   PubMed Web of Science ®Google Scholar
• Fuller BM, Mohr NM, Skrupky L, et al. The use of inhaled prostaglandins in patients with ARDS: a systematic review and meta-analysis. Chest. 2015;147(6):1510–1522.
   PubMed Web of Science ®Google Scholar
• Afshari A, Bastholm Bille A, Allingstrup M. Aerosolized prostacyclins for acute respiratory distress syndrome (ARDS). Cochrane Database Syst Rev. 2017;7:CD007733.
   PubMedGoogle Scholar
• Prescott HC, Calfee CS, Thompson BT, et al. Toward smarter lumping and smarter splitting: rethinking strategies for sepsis and acute respiratory distress syndrome clinical trial design. Am J Respir Crit Care Med. 2016;194(2):147–155.
   PubMed Web of Science ®Google Scholar
• Shankar-Hari M, McAuley DF. Acute respiratory distress syndrome phenotypes and identifying treatable traits. Am J Respir Crit Care Med. 2017;195(3):280–281.
   PubMed Web of Science ®Google Scholar
• Calfee CS, Delucchi K, Parsons PE, et al. Subphenotypes in acute respiratory distress syndrome: latent class analysis of data from two randomised controlled trials. Lancet Respir Med. 2014;2:611–620.
   PubMed Web of Science ®Google Scholar
• Calfee CS, Delucchi KL, Sinha P, et al. Acute respiratory distress syndrome subphenotypes and differential response to simvastatin: secondary analysis of a randomised controlled trial. Lancet Respir Med. 2018;6:691–698.
   PubMed Web of Science ®Google Scholar
• Morrison T, McAuley DF, Krasnodembskaya A. Mesenchymal stromal cells for treatment of the acute respiratory distress syndrome: the beginning of the story. JICS. 2015;16(4):320–329.
   Google Scholar
• Millar JE, Fraser JF, McAuley DF. Mesenchymal stromal cells and the acute respiratory distress syndrome (ARDS): challenges for clinical application. Thorax. 2015;70(7):611–612.
   PubMed Web of Science ®Google Scholar
• The United States Food and Drug Administration. Guidance for industry: enrichment strategies for clinical trials to support approval of human drugs and biological products. 2012. [cited 2019 Feb 8]. Available from: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm332181.pdf
   Google Scholar